NASDAQ:YMAB - Y-mAbs Therapeutics Stock Price, Forecast & News

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) issued its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.54) by $0.16. View Y-mAbs Therapeutics' Earnings History.

Y-mAbs Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for Y-mAbs Therapeutics.

5 brokers have issued 12-month target prices for Y-mAbs Therapeutics' stock. Their forecasts range from $38.00 to $41.00. On average, they expect Y-mAbs Therapeutics' stock price to reach $39.50 in the next year. This suggests a possible upside of 19.8% from the stock's current price. View Analyst Price Targets for Y-mAbs Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Y-mAbs Therapeutics.

Media headlines about YMAB stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Y-mAbs Therapeutics earned a news impact score of 2.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Y-mAbs Therapeutics.

Y-mAbs Therapeutics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 1,500,000 shares, a decrease of 9.1% from the January 15th total of 1,650,000 shares. Based on an average daily volume of 284,800 shares, the short-interest ratio is presently 5.3 days. Currently, 7.7% of the company's shares are short sold. View Y-mAbs Therapeutics' Current Options Chain.

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital Wireless (IDCC), Stag Industrial (STAG), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), JD.Com (JD), Nabriva Therapeutics (NBRV) and Viking Therapeutics (VKTX).

(YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Y-mAbs Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sofinnova Investments Inc. (5.52%), FMR LLC (3.50%), State Street Corp (1.88%), Goldman Sachs Group Inc. (1.45%), Perceptive Advisors LLC (1.42%) and Loomis Sayles & Co. L P (1.37%). Company insiders that own Y-mAbs Therapeutics stock include Ashu Tyagi, James Healy, Johan Wedell-Wedellsborg, Moller San Pedro Claus Juan and Thomas Gad. View Institutional Ownership Trends for Y-mAbs Therapeutics.

YMAB stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, FMR LLC, Renaissance Technologies LLC and Vident Investment Advisory LLC. Company insiders that have sold Y-mAbs Therapeutics company stock in the last year include Johan Wedell-Wedellsborg and Thomas Gad. View Insider Buying and Selling for Y-mAbs Therapeutics.

YMAB stock was acquired by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, State Street Corp, Goldman Sachs Group Inc., Driehaus Capital Management LLC, Sofinnova Investments Inc., Schonfeld Strategic Advisors LLC, Candriam Luxembourg S.C.A. and Rice Hall James & Associates LLC. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include Ashu Tyagi, James Healy and Moller San Pedro Claus Juan. View Insider Buying and Selling for Y-mAbs Therapeutics.

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of YMAB stock can currently be purchased for approximately $32.97.